Zie ook in gerelateerde artikelen hieronder of hiernaast
9 september 2025: Bron: Science Direct
PARP-remmers, voluit Poly-ADP-ribosepolymeraseremmers, blijken bij eierstokkanker als onderhoudsbehandeling als behandeling van deze ziekte bij zowel patiënten met als zonder de homologe recombinatiedeficiëntie voor langere overleving en progressievrije ziekte te zorgen. Meeastal is er sprake van een BRCA 1 of 2 mutatie maar is niet altijd noodzakelijk.
Een overzichtstudie laat zien dat 5 verschillende fase III studies hebben aangetoond dat PARP-remmers zoals olaparib, rucaparib, niraparib o.a. de progressievrije overleving in gevorderde eierstokkanker (HGSOC) in het ontstaan van een recidief en gegeven als onderhoudsbehandeling significant verbeterde. Echter na enkele jaren blijkt toch 40 tot 70 procent van de patiënten resistentie tegen PARP-remmers te ontwikkelen.
In een recente studie wordt inzicht gegeven in welke factoren bijdragen aan het resistent worden voor PARP-remmers. En hoe deze resistentie te voorkomen is. De onderzoekers benadrukken de rol van circulerend tumor-DNA (ctDNA) bij het identificeren van verworven resistentiebiomarkers en de potentie ervan voor het sturen van 'real-time' behandelbeslissingen.
Daarnaast geeft een andere meta-analyse een overzicht van het gebruik van PARP-remmers bij eierstokkanker en worden in het studieverslag ook recente updates besproken over de algehele overlevingsgegevens en hun potentieel als combinatietherapie met anti-angiogene medicijnen en worden de mogelijkheden besproken van immuuntherapie voor eierstokkanker, evenals andere behandelingen om resistentiemechanismen te overwinnen om zodoende de therapeutische werkzaamheid van eierstokkanker te verbeteren.
Hier achtereenvolgens het abstract van de meta-analyse waarvan alleen een uitgebreid abstract is te lezen of tegen betaling het hele studierapport. Daaronder de studie die de resistentie bespreekt die gratis is in te zien of te downloaden. Referenties van beide studies staan onderaan artikel.
PARP inhibitors in ovarian cancer
PARP inhibitors in ovarian cancer
Here, we summarise the current landscape of mechanisms associated with PARPi resistance such as restored homologous recombination repair functionality, replication fork stability and alterations to PARP1 and PARP2 and the DNA damage response.
PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy
Under a Creative Commons license
Open access
referenties meta-analyse studie
There are more references available in the full text version of this article.
Cited by (7)
-
From bench to bedside: Synthetic strategies and clinical application of PARP inhibitors
2025, Bioorganic Chemistry -
Global research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis
2025, Discover Oncology -
The Landscape of PARP Inhibitors in Solid Cancers
2025, Oncotargets and Therapy
Referenties resistentiestudie
References
- [1]
Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global studyCancers, 14 (9) (2022), 10.3390/cancers14092230
- [2]
Global epidemiology of epithelial ovarian cancerNat. Rev. Clin. Oncol., 21 (5) (2024), pp. 389-400, 10.1038/s41571-024-00881-3
- [3]
Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK million women studyCancer Epidemiol., 76 (2022), Article 102074, 10.1016/j.canep.2021.102074
- [4]
Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK collaborative trial of ovarian cancer screening (UKCTOCS)Gynecol. Oncol., 158 (2) (2020), pp. 316-322, 10.1016/j.ygyno.2020.05.002
- [5]
The current status of DNA-repair-directed precision oncology strategies in epithelial ovarian cancersInt. J. Mol. Sci., 24 (8) (2023), 10.3390/ijms24087293
- [6]
Ten-year relative survival for epithelial ovarian cancerObstet. Gynecol., 120 (3) (2012), pp. 612-618, 10.1097/AOG.0b013e318264f794
- [7]
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryJ. Pathol., 221 (1) (2010), pp. 49-56, 10.1002/path.2696
- [8]
Targeting DNA damage repair precision medicine strategies in cancerCurr. Opin. Pharm., 70 (2023), Article 102381, 10.1016/j.coph.2023.102381
- [9]
PARP inhibitor resistance: the underlying mechanisms and clinical implicationsMol. Cancer, 19 (1) (2020), p. 107, 10.1186/s12943-020-01227-0
-
Mechanisms of PARP-inhibitor-resistance in BRCA-mutated Breast cancer and new therapeutic approachesCancers, 15 (14) (2023), 10.3390/cancers15143642
-
PARP inhibitors: clinical limitations and recent attempts to overcome themInt. J. Mol. Sci., 23 (15) (2022), 10.3390/ijms23158412
-
Targeting DNA damage response pathways in cancerNat. Rev. Cancer, 23 (2) (2023), pp. 78-94, 10.1038/s41568-022-00535-5
-
DNA repair in cancer: emerging targets for personalized therapyCancer Manag. Res., 6 (2014), pp. 77-92, 10.2147/CMAR.S50497
-
Cancers exhibit a mutator phenotype: clinical implicationsdiscussion 7Cancer Res., 68 (10) (2008), pp. 3551-3557, 10.1158/0008-5472.CAN-07-5835
-
Morphological and molecular heterogeneity of epithelial ovarian cancer: therapeutic implicationsEJC Suppl., 15 (2020), pp. 1-15, 10.1016/j.ejcsup.2020.02.001
-
Predictive and prognostic value of DNA damage response associated kinases in solid tumorsFront. Oncol., 10 (2020), Article 581217, 10.3389/fonc.2020.581217
-
Ovarian cancer-insights into platinum resistance and overcoming itMedicina, 59 (3) (2023), 10.3390/medicina59030544
-
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancerJ. Natl. Cancer Inst., 95 (17) (2003), pp. 1320-1329, 10.1093/jnci/djg03610.1093/jnci/djg036
-
Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancerFront. Oncol., 14 (2024), Article 1414112, 10.3389/fonc.2024.1414112
-
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic reviewMet. Based Drugs, 2010 (2010), 10.1155/2010/207084
-
Cisplatin in ovarian cancer treatment-known limitations in therapy force new solutionsInt J. Mol. Sci., 24 (8) (2023), 10.3390/ijms24087585
-
Hypersensitivity reactions to chemotherapy: an EAACI position paperAllergy, 77 (2) (2022), pp. 388-403, 10.1111/all.15113
-
Synthetic lethality and cancerNat. Rev. Genet., 18 (10) (2017), pp. 613-623, 10.1038/nrg.2017.47
-
Evolving DNA repair synthetic lethality targets in cancerBiosci. Rep., 42 (12) (2022), 10.1042/BSR20221713
-
Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseasesCrit. Rev. Eukaryot. Gene Expr., 24 (1) (2014), pp. 15-28, 10.1615/critreveukaryotgeneexpr.2013006875
-
Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylationMol. Cell, 58 (6) (2015), pp. 935-946, 10.1016/j.molcel.2015.05.007
-
The multifaceted roles of PARP1 in DNA repair and chromatin remodellingNat. Rev. Mol. Cell Biol., 18 (10) (2017), pp. 610-621, 10.1038/nrm.2017.53
-
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sitesJ. Biol. Chem., 283 (2) (2008), pp. 1197-1208, 10.1074/jbc.M706734200
-
Homologous recombination and the repair of DNA double-strand breaksJ. Biol. Chem., 293 (27) (2018), pp. 10524-10535, 10.1074/jbc.TM118.000372
-
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteinsCold Spring Harb. Perspect. Biol., 7 (4) (2015), p. a016600, 10.1101/cshperspect.a016600
-
PARP1 roles in DNA repair and DNA replication: the basi(c)s of PARP inhibitor efficacy and resistanceSemin Oncol., 51 (1-2) (2024), pp. 2-18, 10.1053/j.seminoncol.2023.08.001
-
PARP-1 activation requires local unfolding of an autoinhibitory domainMol. Cell, 60 (5) (2015), pp. 755-768, 10.1016/j.molcel.2015.10.013
-
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functionsBiochem J., 342 (Pt 2) (1999), pp. 249-268(doi:)
-
Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at drosophila puff lociScience, 299 (5606) (2003), pp. 560-562(doi:)
-
Readers of poly(ADP-ribose): designed to be fit for purposeNucleic Acids Res, 44 (3) (2016), pp. 993-1006, 10.1093/nar/gkv1383
-
Serine-linked PARP1 auto-modification controls PARP inhibitor responseNat. Commun., 12 (1) (2021), p. 4055, 10.1038/s41467-021-24361-9
-
The role of poly ADP-ribosylation in the first wave of DNA damage responseNucleic Acids Res, 45 (14) (2017), pp. 8129-8141, 10.1093/nar/gkx565
-
The role of PARP in DNA repair and its therapeutic exploitationBr. J. Cancer, 105 (8) (2011), pp. 1114-1122, 10.1038/bjc.2011.382
-
PARP2 mediates branched poly ADP-ribosylation in response to DNA damageNat. Commun., 9 (1) (2018), p. 3233, 10.1038/s41467-018-05588-5
-
The expanding universe of PARP1-mediated molecular and therapeutic mechanismsMol. Cell, 82 (12) (2022), pp. 2315-2334, 10.1016/j.molcel.2022.02.021
-
Poly(ADP-ribose) polymerase inhibition: past, present and futureNat. Rev. Drug Discov., 19 (10) (2020), pp. 711-736, 10.1038/s41573-020-0076-6
-
The molecular mechanisms of actions, effects, and clinical implications of parp inhibitors in epithelial ovarian cancers: a systematic reviewInt J. Mol. Sci., 23 (15) (2022), 10.3390/ijms23158125
-
Mechanisms of DNA-protein crosslink repairNat. Rev. Mol. Cell Biol., 18 (9) (2017), pp. 563-573, 10.1038/nrm.2017.56
-
Structural basis for allosteric PARP-1 retention on DNA breaksScience, 368 (6486) (2020), 10.1126/science.aax6367
-
Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent diseaseFuture Oncol., 14 (30) (2018), pp. 3101-3110, 10.2217/fon-2018-0215
-
PARP Inhibitors in the treatment of triple-negative breast cancerClin. Pharm., 57 (4) (2018), pp. 427-437, 10.1007/s40262-017-0587-4
-
Trapping of PARP1 and PARP2 by clinical PARP inhibitorsCancer Res, 72 (21) (2012), pp. 5588-5599, 10.1158/0008-5472.CAN-12-2753
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434 (7035) (2005), pp. 917-921, 10.1038/nature03445
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 434 (7035) (2005), pp. 913-917, 10.1038/nature03443
-
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiencyMol. Cell, 81 (15) (2021), pp. 3128-3144 e7, 10.1016/j.molcel.2021.06.01110.1016/j.molcel.2021.06.011. Epub 2021 Jul 2
-
Transcription-replication conflicts underlie sensitivity to PARP inhibitorsNature, 628 (8007) (2024), pp. 433-441, 10.1038/s41586-024-07217-2
-
Poly(ADP-ribosyl)ation of timeless limits DNA replication stress and promotes stalled fork protectionCell Rep., 43 (3) (2024), Article 113845, 10.1016/j.celrep.2024.113845
-
BRCAness revisitedNat. Rev. Cancer, 16 (2) (2016), pp. 110-120, 10.1038/nrc.2015.21
-
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and managementClinics, 73 (1) (2018), Article e450s, 10.6061/clinics/2018/e450s
-
BRACAnalysis CDx as a companion diagnostic tool for LynparzaExpert Rev. Mol. Diagn., 15 (9) (2015), pp. 1111-1116, 10.1586/14737159.2015.1078238
-
A profile on the foundationfocus CDxBRCA testsExpert Rev. Mol. Diagn., 20 (3) (2020), pp. 285-292, 10.1080/14737159.2020.1701438
-
Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancerClin. Cancer Res, 22 (15) (2016), pp. 3764-3773, 10.1158/1078-0432.CCR-15-247710.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8
-
Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high-grade serous ovarian carcinomaClin. Cancer Res, 27 (11) (2021), pp. 3201-3214, 10.1158/1078-0432.CCR-20-4068
-
Toward more comprehensive homologous Recombination Deficiency Assays in Ovarian Cancer, part 1: technical considerationsCancers, 14 (5) (2022), 10.3390/cancers14051132
-
Biomarkers for homologous recombination deficiency in cancerJ. Pers. Med, 11 (7) (2021), 10.3390/jpm11070612
-
Validation of the clinical use of GIScar, an academic-developed genomic instability score predicting sensitivity to maintenance olaparib for ovarian cancerClin. Cancer Res, 29 (21) (2023), pp. 4419-4429, 10.1158/1078-0432.CCR-23-0898
-
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signaturesNat. Med, 23 (4) (2017), pp. 517-525, 10.1038/nm.4292
-
Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approachesFront Oncol., 14 (2024), Article 1405361, 10.3389/fonc.2024.1405361
-
Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trialsWorld J. Surg. Oncol., 21 (1) (2023), p. 157, 10.1186/s12957-023-03027-4
-
PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers1758835920944116Ther. Adv. Med Oncol., 12 (2020), 10.1177/1758835920944116
-
PARP inhibitors in the management of ovarian cancer: ASCO guidelineJ. Clin. Oncol., 38 (30) (2020), pp. 3468-3493, 10.1200/JCO.20.01924
-
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancerN. Engl. J. Med, 379 (26) (2018), pp. 2495-2505, 10.1056/NEJMoa181085810.1056/NEJMoa1810858. Epub 2018 Oct 21
-
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol., 22 (12) (2021), pp. 1721-1731, 10.1016/S1470-2045(21)00531-3
-
Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trialJ. Clin. Oncol., 41 (3) (2023), pp. 609-617, 10.1200/JCO.22.01549
-
Olaparib plus bevacizumab as first-line maintenance in ovarian cancerN. Engl. J. Med, 381 (25) (2019), pp. 2416-2428, 10.1056/NEJMoa1911361
-
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncol., 18 (9) (2017), pp. 1274-1284, 10.1016/S1470-2045(17)30469-2
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialAnn. Oncol., 34 (8) (2023), pp. 681-692, 10.1016/j.annonc.2023.05.005
-
Niraparib in patients with newly diagnosed advanced ovarian cancerN. Engl. J. Med, 381 (25) (2019), pp. 2391-2402, 10.1056/NEJMoa1910962
-
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerEur. J. Cancer, 189 (2023), Article 112908, 10.1016/j.ejca.2023.04.024
-
A Randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)JCO2201003J. Clin. Oncol. (2022), 10.1200/JCO.22.01003
-
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancerN. Engl. J. Med, 375 (22) (2016), pp. 2154-2164, 10.1056/NEJMoa1611310
-
#161 Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancerInt J. Gynecol. Cancer, 33 (3) (2023), pp. A15-A16, 10.1136/ijgc-2023-ESGO.22
-
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trialEClinicalmedicine, 72 (2024), Article 102629, 10.1016/j.eclinm.2024.102629
-
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncol., 22 (5) (2021), pp. 620-631, 10.1016/S1470-2045(21)00073-5
-
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trialAnn. Oncol. (2023), 10.1016/j.annonc.2023.09.3110
-
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialLancet, 390 (10106) (2017), pp. 1949-1961, 10.1016/S0140-6736(17)32440-6
-
O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinomaInt J. Gynecol. Cancer, 32 (3) (2022), pp. A3-A4, 10.1136/ijgc-2022-igcs.5
-
A decade of clinical development of PARP inhibitors in perspectiveAnn. Oncol., 30 (9) (2019), pp. 1437-1447, 10.1093/annonc/mdz192
-
Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancerN. Engl. J. Med, 381 (25) (2019), pp. 2403-2415, 10.1056/NEJMoa1909707
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studyGynecol. Oncol., 164 (2) (2022), pp. 245-253, 10.1016/j.ygyno.2021.12.003
-
Fuzuloparib: first approvalDrugs, 81 (10) (2021), pp. 1221-1226, 10.1007/s40265-021-01541-x
-
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trialBr. J. Cancer, 129 (5) (2023), pp. 797-810, 10.1038/s41416-023-02349-0
-
An open-label, multicenter, single-arm, phase ii study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancerClin. Cancer Res, 27 (9) (2021), pp. 2452-2458, 10.1158/1078-0432.CCR-20-3546
-
Pamiparib monotherapy for patients with germline BRCA1/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase ii studyClin. Cancer Res, 28 (4) (2022), pp. 653-661, 10.1158/1078-0432.CCR-21-1186
-
Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (fzocus-2): a multicenter, randomized, double-blind, placebo-controlled, phase iii trialJ. Clin. Oncol., 40 (22) (2022), pp. 2436-2446, 10.1200/JCO.21.01511
-
Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancerJ. Clin. Oncol., 40 (16_) (2022), p. 5552, 10.1200/JCO.2022.40.16_suppl.5552
-
Exploring and comparing adverse events between PARP inhibitorsLancet Oncol., 20 (1) (2019), pp. e15-e28, 10.1016/S1470-2045(18)30786-1
-
Managing adverse effects associated with poly (adp-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world dataAm. Soc. Clin. Oncol. Educ. Book (43) (2023), Article e390876, 10.1200/edbk_390876
-
Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trialsAnn. Transl. Med, 9 (15) (2021), p. 1229(doi:)
-
Real-world outcomes associated with poly(adp-ribose) polymerase inhibitor monotherapy maintenance in patients with primary advanced ovarian cancerAm. J. Clin. Oncol., 46 (7) (2023), pp. 314-322, 10.1097/COC.0000000000001010
-
Real-world progression-free and overall survival for patients with advanced ovarian cancer utilizing PARP inhibitor second-line maintenance therapy vs active surveillance(e)J. Clin. Oncol., 40 (16_) (2022), Article e18812, 10.1200/JCO.2022.40.16_suppl.e18812
-
EVOLVE: a multicenter open-label single-arm clinical and translational phase ii trial of cediranib plus olaparib for ovarian cancer after parp inhibition progressionClin. Cancer Res, 26 (16) (2020), pp. 4206-4215, 10.1158/1078-0432.CCR-19-4121
-
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceAnn. Oncol., 32 (1) (2021), pp. 103-112, 10.1016/j.annonc.2020.10.470
-
Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistanceCancer Discov., 10 (10) (2020), pp. 1475-1488, 10.1158/2159-8290.CD-19-1485
-
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceMol. Cancer, 23 (1) (2024), p. 158, 10.1186/s12943-024-02048-1
-
Modeling therapy resistance in brca1/2-mutant cancersMol. Cancer Ther., 16 (9) (2017), pp. 2022-2034, 10.1158/1535-7163.MCT-17-0098
-
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Nat. Commun., 12 (1) (2021), p. 2487, 10.1038/s41467-021-22582-6
-
Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatmentNAR Cancer, 4 (4) (2022), Article zcac042, 10.1093/narcan/zcac042
-
Secondary somatic mutations restoring rad51c and rad51d associated with acquired resistance to the parp inhibitor rucaparib in high-grade ovarian carcinomaCancer Discov., 7 (9) (2017), pp. 984-998, 10.1158/2159-8290.CD-17-0419
-
Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesisNat. Struct. Mol. Biol., 17 (11) (2010), pp. 1305-1311, 10.1038/nsmb.1927
-
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenograftsBr. J. Cancer, 126 (1) (2022), pp. 120-128, 10.1038/s41416-021-01609-1
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationEMBO Mol. Med, 10 (12) (2018), 10.15252/emmm.201809172
-
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerAnn. Oncol., 29 (5) (2018), pp. 1203-1210, 10.1093/annonc/mdy099
-
PARP inhibitor resistance in breast and gynecological cancer: resistance mechanisms and combination therapy strategiesFront. Pharm., 13 (2022), Article 967633, 10.3389/fphar.2022.967633
-
Mechanisms of therapy resistance in patient-derived xenograft models of brca1-deficient breast cancerJ. Natl. Cancer Inst., 108 (11) (2016), 10.1093/jnci/djw148
-
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaNat. Commun., 9 (1) (2018), p. 3970, 10.1038/s41467-018-05564-z
-
Acquired RAD51C promoter methylation loss causes parp inhibitor resistance in high-grade serous ovarian carcinomaCancer Res, 81 (18) (2021), pp. 4709-4722, 10.1158/0008-5472.CAN-21-0774
-
RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?Expert Rev. Mol. Diagn., 22 (2) (2022), pp. 185-199, 10.1080/14737159.2022.2020102
-
RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resectionMol. Cell, 49 (5) (2013), pp. 858-871, 10.1016/j.molcel.2013.01.002
-
REV7 counteracts DNA double-strand break resection and affects PARP inhibitionNature, 521 (7553) (2015), pp. 541-544, 10.1038/nature14328
-
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cellsNat. Cell Biol., 20 (8) (2018), pp. 954-965, 10.1038/s41556-018-0140-1
-
The shieldin complex mediates 53BP1-dependent DNA repairNature, 560 (7716) (2018), pp. 117-121, 10.1038/s41586-018-0340-7
-
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cellsNature, 563 (7732) (2018), pp. 522-526, 10.1038/s41586-018-0670-5
-
RADX promotes genome stability and modulates chemosensitivity by regulating rad51 at replication forksMol. Cell, 67 (3) (2017), pp. 374-386 e5, 10.1016/j.molcel.2017.06.023
-
Replication fork stability confers chemoresistance in BRCA-deficient cellsNature, 535 (7612) (2016), pp. 382-387, 10.1038/nature18325
-
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage responseBr. J. Cancer, 124 (5) (2021), pp. 857-859, 10.1038/s41416-020-01202-y
-
SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitorsProc. Natl. Acad. Sci., 118 (6) (2021), Article e2015654118, 10.1073/pnas.2015654118
-
Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forksOncogene, 43 (32) (2024), pp. 2475-2489, 10.1038/s41388-024-03094-1
-
resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibitionOncotarget, 7 (47) (2016), pp. 76534-76550, 10.18632/oncotarget.12266
-
PARP inhibitor activity correlates with slfn11 expression and demonstrates synergy with temozolomide in small cell lung cancerClin. Cancer Res, 23 (2) (2017), pp. 523-535, 10.1158/1078-0432.CCR-16-1040
-
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerOncotarget, 8 (17) (2017), pp. 28575-28587, 10.18632/oncotarget.15338
-
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivoJ. Cancer Res Clin. Oncol., 146 (7) (2020), pp. 1659-1670, 10.1007/s00432-020-03211-z
-
Randomized, double-blind, phase ii study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancerJ. Clin. Oncol., 36 (23) (2018), pp. 2386-2394, 10.1200/JCO.2018.77.7672
-
CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombinationNAR Cancer, 5 (3) (2023), Article zcad039, 10.1093/narcan/zcad039
-
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibitionNature, 604 (7907) (2022), pp. 749-756, 10.1038/s41586-022-04638-9
-
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306J. Med. Chem., 65 (15) (2022), pp. 10251-10284, 10.1021/acs.jmedchem.2c00552
-
Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we standJ. Hematol. Oncol., 12 (1) (2019), p. 43, 10.1186/s13045-019-0733-6
-
ATR/CHK1 inhibitors and cancer therapyRadio. Oncol., 126 (3) (2018), pp. 450-464, 10.1016/j.radonc.2017.09.043
-
Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transitionMol. Cell Biol., 25 (13) (2005), pp. 5725-5737, 10.1128/MCB.25.13.5725-5737.2005
-
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer modelsNat. Commun., 11 (1) (2020), p. 3726, 10.1038/s41467-020-17127-2
-
HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancerCell Death Dis., 13 (3) (2022), p. 263, 10.1038/s41419-022-04670-7
-
Targeting the high-mobility group box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatinCancer Res., 79 (13) (2019), pp. 3185-3191, 10.1158/0008-5472.CAN-19-0542
-
Poltheta inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceNat. Commun., 12 (1) (2021), p. 3636, 10.1038/s41467-021-23463-8
-
Beyond PARP-POLtheta as an anticancer targetScience, 359 (6381) (2018), pp. 1217-1218, 10.1126/science.aar5149
-
Homologous-recombination-deficient tumours are dependent on poltheta-mediated repairNature, 518 (7538) (2015), pp. 258-262, 10.1038/nature14184
-
Poltheta: emerging synthetic lethal partner in homologous recombination-deficient tumorsCancer Gene Ther. (2024), 10.1038/s41417-024-00815-2
-
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceNat. Commun., 9 (1) (2018), p. 1849, 10.1038/s41467-018-03917-2
-
Selective loss of parg restores parylation and counteracts parp inhibitor-mediated synthetic lethalityCancer Cell, 33 (6) (2018), pp. 1078-1093 e12, 10.1016/j.ccell.2018.05.008
-
Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activationNat. Commun., 4 (2013), p. 2993, 10.1038/ncomms3993
-
DNA replication vulnerabilities render ovarian cancer cells sensitive to poly(adp-ribose) glycohydrolase inhibitorsCancer Cell, 35 (3) (2019), pp. 519-533 e8, 10.1016/j.ccell.2019.02.004
-
Serine is the major residue for ADP-ribosylation upon DNA damageElife, 7 (2018), 10.7554/eLife.34334
-
Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesionse2322689121Proc. Natl. Acad. Sci., 121 (25) (2024), 10.1073/pnas.2322689121
-
High-throughput screening assay for PARP-HPF1 interaction inhibitors to affect DNA damage repairSci. Rep., 14 (1) (2024), p. 3875, 10.1038/s41598-024-54123-8
-
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancerNat. Commun., 10 (1) (2019), p. 1295, 10.1038/s41467-019-09312-9
-
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cellsBr. J. Cancer, 115 (4) (2016), pp. 431-441, 10.1038/bjc.2016.203
-
PARP inhibitors as p-glyoprotein substratesJ. Pharm. Sci., 103 (6) (2014), pp. 1913-1920, 10.1002/jps.23952
-
The role of ABC transporters in ovarian cancer progression and chemoresistanceCrit. Rev. Oncol. Hematol., 96 (2) (2015), pp. 220-256, 10.1016/j.critrevonc.2015.05.012
-
Abstract 5338: pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cellsCancer Res., 82 (12_ement) (2022), p. 5338, 10.1158/1538-7445.Am2022-5338
-
Using cfDNA and ctDNA as oncologic markers: a path to clinical validationInt. J. Mol. Sci., 24 (17) (2023), 10.3390/ijms241713219
-
Identifying mechanisms of resistance by circulating tumor DNA in EVOLVE, a phase II trial of cediranib plus olaparib for ovarian cancer at time of parp inhibitor progressionClin. Cancer Res., 29 (18) (2023), pp. 3706-3716, 10.1158/1078-0432.CCR-23-0797
-
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?Semin Cancer Biol., 77 (2021), pp. 67-82, 10.1016/j.semcancer.2021.02.008
-
BRCA Reversion mutations in circulating tumor dna predict primary and acquired resistance to the parp inhibitor rucaparib in high-grade ovarian carcinomaCancer Discov., 9 (2) (2019), pp. 210-219, 10.1158/2159-8290.CD-18-0715
-
The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapyHeliyon, 6 (5) (2020), Article e03841, 10.1016/j.heliyon.2020.e03841
-
Diverse brca1 and brca2 reversion mutations in circulating cell-free dna of therapy-resistant breast or ovarian cancerClin. Cancer Res., 23 (21) (2017), pp. 6708-6720, 10.1158/1078-0432.CCR-17-0544
-
Reversion of BRCA1/2 germline mutations detected in circulating tumor dna from patients with high-grade serous ovarian cancerJ. Clin. Oncol., 35 (12) (2017), pp. 1274-1280, 10.1200/JCO.2016.70.4627
-
Investigation of parp inhibitor resistance based on serially collected circulating tumor dna in patients with brca-mutated ovarian cancerClin. Cancer Res., 29 (14) (2023), pp. 2725-2734, 10.1158/1078-0432.CCR-22-3715
-
Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: a single institutional experienceGynecol. Oncol. Rep., 40 (2022), Article 100939, 10.1016/j.gore.2022.100939
-
PARPi after PARPi in epithelial ovarian cancerGynecol. Oncol. Rep., 35 (2021), Article 100699, 10.1016/j.gore.2021.100699
-
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groupsInt J. Gynecol. Cancer, 32 (6) (2022), pp. 799-803, 10.1136/ijgc-2022-003435
-
T. Yap, A. Schram, J. Balmana, A. Falcon, J. Corbacho, S. Im, et al., editors. CT014—PETRA: First-in-human Phase 1/2a trial of the first-in-class new generation poly (ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations. Proceedings of the American Association for Cancer research Annual Meeting, San Diego, CA, USA; 2024.
-
Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations(-CT)Cancer Res, 82 (12_ement) (2022), p. CT007, 10.1158/1538-7445.Am2022-ct007
-
Targeting the DNA damage response for cancer therapyBiochem. Soc. Trans., 51 (1) (2023), pp. 207-221, 10.1042/BST20220681
-
A synthetic lethal screen identifies dna repair pathways that sensitize cancer cells to combined atr inhibition and cisplatin treatmentsPLoS One, 10 (5) (2015), Article e0125482, 10.1371/journal.pone.0125482
-
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2(MUT) ovarian cancer cellsSci. Rep., 13 (1) (2023), Article 22659, 10.1038/s41598-023-50151-y
-
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialLancet Oncol., 21 (7) (2020), pp. 957-968, 10.1016/S1470-2045(20)30180-7
-
Combination ATR (ceralasertib) and parp (olaparib) inhibitor (capri) trial in acquired parp inhibitor-resistant homologous recombination-deficient ovarian cancerClin. Cancer Res., 29 (15) (2023), pp. 2800-2807, 10.1158/1078-0432.CCR-22-2444
-
A phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancerGynecol. Oncol., 167 (2) (2022), pp. 213-225, 10.1016/j.ygyno.2022.09.019
-
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): an open label, four-arm, phase II studyJ. Clin. Oncol., 37 (15_) (2019), p. 5513, 10.1200/JCO.2019.37.15_suppl.5513
-
Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase ii studyClin. Cancer Res., 28 (1) (2022), pp. 36-44, 10.1158/1078-0432.CCR-21-0158
-
A biomarker-enriched, randomized phase ii trial of adavosertib (azd1775) plus paclitaxel and carboplatin for women with platinum-sensitive tp53-mutant ovarian cancerClin. Cancer Res., 26 (18) (2020), pp. 4767-4776, 10.1158/1078-0432.CCR-20-0219
-
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trialLancet, 397 (10271) (2021), pp. 281-292, 10.1016/S0140-6736(20)32554-X
-
PO003/#269 Ignite: a phase II signal-seeking trial of adavosertib targeting recurrent high grade serous ovarian cancer with cyclin E1 over-expression with and without gene amplificationInt. J. Gynecol. Cancer, 33 (4) (2023), pp. A2-A3, 10.1136/ijgc-2023-IGCS.3
-
Clinical development of WEE1 inhibitors in gynecological cancers: a systematic reviewCancer Treat. Rev., 115 (2023), Article 102531, 10.1016/j.ctrv.2023.102531
-
EFFORT: efficacy of adavosertib in parp resistance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with parp-resistant ovarian cancerJ. Clin. Oncol., 39 (15_) (2021), p. 5505, 10.1200/JCO.2021.39.15_suppl.5505
-
Discovery of a small-molecule inhibitor that traps poltheta on DNA and synergizes with PARP inhibitorsNat. Commun., 15 (1) (2024), p. 2862, 10.1038/s41467-024-46593-1
-
53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancerNat. Commun., 15 (1) (2024), p. 6676, 10.1038/s41467-024-50999-2
-
Treatment of ovarian cancer beyond parp inhibition: current and future optionsDrugs, 83 (15) (2023), pp. 1365-1385, 10.1007/s40265-023-01934-0
-
Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvantFront. Immunol. (11) (2020), Article 577869, 10.3389/fimmu.2020.577869
Cited by (2)
© 2025 The Author(s). Published by Elsevier B.V.
Gerelateerde artikelen
- Parpremmers bij eierstokkanker: een meta analyse biedt een overzicht welke vorm van eierstokkanker gevoelig blijkt en welke niet. En hoe resistentie optreedt bespreekt een andere studie
- Parpremmers olaparib (Lynparza®) of niraparib (Zejula®) voor eierstokkanker en borstkanker worden gedeeltelijk uit basisverzekering gehaald door Zorginstituut Nederland copy 1
- Olaparib herhalen bij patienten met gevorderde eierstokkanker die al eerder olaparib en chemo hebben gehad blijkt alsnog effectief in vergelijking met placebo
- Niraparib als eerstelijns onderhoudsbehandeling bij patiënten met nieuw gediagnosticeerde gevorderde operabele eierstokkanker verdubbelt op 5 jaar ziektevrije overleving in vergelijking met placebo
- Niraparib - Zejula als onderhoudsbehandeling bij gevorderde eierstokkanker geeft een veel langere progressievrije overleving bij zowel patiënten met BRCA-gemuteerde eierstokkanker als bij niet BRCA-gemuteerd
- niraparib plus bevacizumab (Avastin) zonder chemo of gegeven in chemovrije periode verdubbelt bij eierstokkanker ziektevrije tijd en ziektevrije overleving steeg met 26 procent (79 vs 53 procent)
- Niraparib geeft zeer goede resultaten bij recidief van gevorderde eierstokkanker die eerder gevoelig bleek voor op platinum gebaseerde chemo copy 1
- Parpremmers Olaparib en niraparib gegeven als onderhoudsbehandeling bij gevorderde chemo gevoelige eierstokkanker heeft geen negatief effect op kwaliteit van leven en geeft wel betere overall overleving
- PARP remmers zoals olaparib zouden in vroeger stadium van eierstokkanker en andere vormen van kanker met BRCA mutaties moeten worden ingezet want teveel chemokuren verminderen kans op aanslaan van de behandeling, stellen oncologen n.a.v. diverse studies
- Talazoparib, een PARP remmer, wordt in veel studies bij veel verschillende vormen van kanker en in combinatie met andere medicijnen onderzocht en geeft veelbelovende resultaten copy 1
- Olaparib plus Bevacizumab als eerstelijns onderhoudsbehandeling voor eierstokkanker geeft betere progressievrije ziekte dan placebo ongeacht BRCA status.
- Olaparib als onderhoudsbehandeling voor BRCA 1/2 uitgezaaide platinum gevoelige eierstokkanker geeft 70 procent minder kans op overlijden in vergelijking met placebo
- Olaparib, een PARP remmer, verlengt ziektevrije en overall overleving in vergelijking met placebo bij eierstokkanker met BRCA 1 en 2
- Olaparib plus cedinarib lijkt doorbraak bij controle van vergevorderde eierstokkanker en verdubbelt progressievrije overleving van 9,2 maanden naar 17,7 maanden
- Parpremmer niraparib naast chemo en daarna als onderhoudsbehandeling verdubbelt mediane overall overleving in vergelijking met placebo
- Parpremmer Veliparib naast chemo gevolgd door veliparib alleen als onderhoudsbehandeling geeft betere overall overleving voor patienten met eierstokkanker stadium III en IV.
- Patienten met gevorderde eierstokkanker met een PARP-7 mutatie / expressie blijken veel betere mediane overall overleving te hebben (45 vs 16 maanden) dan zonder PARP-7 mutatie / expressie. copy 1
- Parpremmer rucaparib verdubbelt ziektevrije overleving (5 vs 11 en 13 maanden) bij chemo gevoelige eierstokkanker. Ook bij patienten zonder BRCA mutatie is rucaparib effectief
- PARP remmers zoals olaparib zouden in vroeger stadium van eierstokkanker en andere vormen van kanker met BRCA mutaties moeten worden ingezet
- BRCA - erfelijkheid: Combinatie van sapacitabine en seliciclib geeft een hoopvol therapeutisch effect bij zwaar voorbehandelde kankerpatienten met solide tumoren met onderliggende afwijkende erfelijke BCRA gen mutaties. copy 1
- PARP remmers zoals olaparib, niraparib en rucaparib zijn effectief zowel met als zonder BRCA mutaties, een overzicht
Plaats een reactie ...
Reageer op "Parpremmers bij eierstokkanker: een meta analyse biedt een overzicht welke vorm van eierstokkanker gevoelig blijkt en welke niet. En hoe resistentie optreedt bespreekt een andere studie"